Three multigene expression signatures (IFN-γ, expanded immune and T-cell-inflamed signature) have been associated with clinical benefit from anti-PD-1 treatment in several cancer types.22 Importantly, patients rendering TR TIL products exhibited significantly higher scores for the three mentioned signatures, in particular for the T-cell inflamed GEP. The gene discussed is PDCD1; the disease is cancer.